SU178761A1 - - Google Patents
Info
- Publication number
- SU178761A1 SU178761A1 SU633050A SU633050A SU178761A1 SU 178761 A1 SU178761 A1 SU 178761A1 SU 633050 A SU633050 A SU 633050A SU 633050 A SU633050 A SU 633050A SU 178761 A1 SU178761 A1 SU 178761A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- carbomethoxyethylhydrazine
- nialamide
- ethyl acetate
- benzyl
- sarcoses
- Prior art date
Links
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- NOIIUHRQUVNIDD-UHFFFAOYSA-N Nialamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 3
- 229960003057 Nialamide Drugs 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N Beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Description
Известен способ получени Н-беизил-р-(изокикотиноилгндразин ) - пропнонамида(ниаламида ), используемого в качестве средства дл лечени психических заболеваиий (антндепрессант ) и грудной жабы.A known method for producing N-beisyl-p- (isocotinoylgndrazine) -propnonamide (nialamide) is used as a treatment for mental illness (antdepressant) and angina pectoris.
Предложено 1-изоникотинонл-2-карбометоксиэтилгидразин подвергать взаимодействию с бензиламииом при 130°С прн перемешивании с последующей нерекристаллизацией из этилацетата .It has been proposed to react 1-isonicotinon-2-carbomethoxyethylhydrazine with benzylamimium at 130 ° C. under stirring followed by non-recrystallization from ethyl acetate.
Исходный 1-изопнкотнпонл-2-карбометоксиэтилгидразин может быть получен, например, конденсацией нзоникотиноплгндразпда с .ieтилметакрилатом .The starting 1-isoprecot-2-carbomethoxyethylhydrazine can be obtained, for example, by condensation of nzonicotinoplgd razpda with. Methyl methyl acrylate.
Примен ют ниаламид в виде таблеток нли капсул, содержащих 10-150 мг препарата и изготовлеиных известными приемами с использованием обычных фармацевтических наполнителей , например саркозы (80,3 вес. ч.).Nialamide is used in the form of tablets or capsules containing 10-150 mg of the preparation and made by known methods using conventional pharmaceutical excipients, for example, sarcoses (80.3 parts by weight).
крахмала (13,2 вес. ч.) и стеарата магни (6,5 вес. ч.).starch (13.2 wt. h.) and magnesium stearate (6.5 wt. h.).
Пример. Смесь 7,5 г (0,034 моль) 1-изоиикотн1ЮНЛ-2-карбометокспэтилгндразииа и 5 мл беизиламииа патревают в течеппе 3 час при неремешиваи1П1 ii тедтературе 130°С. Охлажденную массу нерекр11сталлпзовывают из этплацетата. Получают ниаламид в виде белых игл с т. пл. 151,1 -152,1°С.Example. A mixture of 7.5 g (0.034 mol) of 1-iso-ikotn-1NLL-2-carbomethoxyethylgndrazia and 5 ml of beisilamia patria is left for 3 hours with an unmixing of 120 ° C. The cooled mass is uncorrected from ethyl acetate. Get nialamide in the form of white needles with so pl. 151.1 -152.1 ° C.
П р е д 1 е т 1 3 о б р е т е н и PRIOR 1 ET 1 3 ABOUT IT
Способ получени К-бензил-р-(изоникотипонлгндразнп ) -пропнопампда (ниаламнда), ог .тчающийс тем, что 1-изоннкотниоил-2-карбометоксиэтилгидразин подвергают взанмодействию с бензиламнном нри 130°С прп перемеипизапнп с последующей перекрнсталлпзацпей из этилацетата.The method of obtaining K-benzyl-p- (isonicotype-group) -propnopampda (nialamna), due to the fact that 1-isonncotnioyl-2-carbomethoxyethylhydrazine is subjected to action with benzylamine at 130 ° C of prepmerase of amectuspylmecidramecidpine hydrochloride, with a benzyl amide of 130 ° C.
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU792792633A Addition SU830468A2 (en) | 1979-07-09 | 1979-07-09 | Shaft angular position-to-code converter |
Publications (1)
Publication Number | Publication Date |
---|---|
SU178761A1 true SU178761A1 (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1309555B1 (en) | Process for making amlodipine maleate | |
US5607969A (en) | L-DOPA ethyl ester to treat Parkinson's disease | |
DE60223923T3 (en) | PROGRUGS OF GABA ANALOGUE, COMPOSITIONS AND ITS USES | |
US5631296A (en) | Drugs containing S(+)-ibuprofen | |
CA2535150C (en) | Non-hygroscopic, stable meldonium salts, method of preparation and pharmaceutical compositions thereof | |
RU2241701C1 (en) | Amlodipine camsylate, method for its preparing and pharmaceutical composition based on thereof | |
EA021763B1 (en) | Solid pharmaceutical composition comprising amlodipine and losartan with improved stability | |
CH629479A5 (en) | TAURIN DERIVATIVES, MEDICAMENT CONTAINING THESE DERIVATIVES AND PROCESS FOR PREPARING THESE DERIVATIVES. | |
MX2007010093A (en) | Amorphous lercanidipine hydrochloride. | |
US6828339B2 (en) | Amlodipine salt forms and processes for preparing them | |
SU178761A1 (en) | ||
NO874733L (en) | SALT OF DICLOFENAC WITH A CYCLIC ORGANIC BASE, AND PHARMACEUTICAL PREPARATIONS CONTAINING THIS. | |
WO2002053135A1 (en) | Amlodipine free base | |
US6479525B2 (en) | Aspartate derivative of amlodipine | |
NO144586B (en) | MANAGEMENT SYSTEM FOR A HYDROFOIL VESSEL. | |
CA2433193C (en) | Amide derivative of amlodipine | |
EP0384088B1 (en) | (+)1-[(3,4,5-Trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylamine, process for its preparation and its therapeutical use | |
AU2009321384A1 (en) | Polymorphs | |
RU2005115920A (en) | METHOD FOR PRODUCING A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION POSSESSING IMPROVED BIOAVAILABILITY OF A BIOLOGICALLY ACTIVE ACTING MEDICINE AND A PHARMACEUTICAL COMPOSITION ESPECIALLY | |
AU2001100432A4 (en) | Process for making amlodipine maleate | |
TWI648278B (en) | Cysteine protease inhibitor salt | |
JPS6341392B2 (en) | ||
JPH0480026B2 (en) | ||
JP2023515583A (en) | Compositions containing methylphenidate prodrugs, methods of making and using the same | |
BE831654A (en) | NEW QUINAZOLINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM |